Pharmafile Logo
Pharmafocus logo
Advanced Search
pharmafocus_sept_2016_cover

The September issue of Pharmafocus is now live!

August 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

News

AstraZeneca to pay £5.52 million to settle bribery probe

August 31, 2016
Research and Development AstraZeneca, SEC, misconduct

According to US regulators, AstraZeneca is to pay $5.52 million to resolve a foreign bribery probe investigating payments made to …

News
novartis_building

FDA approves Novartis Enbrel biosimilar

August 31, 2016
Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli

Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …

News
teva_copy

Teva to lay off 236 in Pomona, New York

August 30, 2016
Manufacturing and Production, Research and Development Teva, closure

Teva is currently in the process of winding down operations at its manufacturing plant in Pomona, New York as it …

News

UK asthma spending tops £1.1 billion

August 30, 2016
Research and Development asthma, university of edinburgh

The University of Edinburgh has released a report that claims UK health service spending on asthma has reached £1.1 billion …

News
shkreli_kalobios

KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan

August 30, 2016
Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround

Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …

News
pancreatic_cancer_research

Heart disease drug development is falling

August 30, 2016
Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development

The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …

News

Cipla receives FDA approval for generic version of Valeant antidepressant

August 30, 2016
Manufacturing and Production, Sales and Marketing Cipla, FDA, Valeant, Wellbutrin

Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the …

News
amgen_hq

Amgen’s Prolia achieves positive top-line Phase III results after 12 months

August 30, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …

News
clinical_trial-web

Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target

August 30, 2016
Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III

Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …

News
asthma_inhalers

Vectura asthma treatment fails at Phase III

August 30, 2016
Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura

Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …

News
top_ten

Top ten stories in the pharmaceutical industry this week

August 26, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10

If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …

News
lab

EMA accepts regulatory submission for proposed Herceptin biosimilar

August 26, 2016
Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab

Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …

News
clinical_trial_4

Denali Therapeutics secures another $130 million for neurodegenerative disease research

August 26, 2016
Medical Communications

Denali Therapeutics has announced a string of collaborations and financing deals worth $130 million that will see the biotech, which …

News
takeda_tokyo_hq

Jobs to go at Takeda as it shuts down Cambridge facility

August 26, 2016
Manufacturing and Production, Medical Communications Cambridge, Jobs, Takeda, closure

Takeda has announced plans to close its facility in Cambridge in the UK, to refocus its research and development operations …

News
mylan_building

Mylan announces immediate plans to cut price of EpiPen

August 25, 2016
Medical Communications, Research and Development Mylan, clinton, epipen, increase

Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …

News
chemo-web

Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer

August 25, 2016
Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib

Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …

News
novartis_malaria_researcher

Positive Phase III results for Novartis MS drug

August 25, 2016
Research and Development Novartis, multiple sclerosis, phase III

Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …

News
teva_copy

Teva loses patent protection on lucrative MS treatment

August 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …

News
amgen_flag

FDA says no to Amgen’s Parsabiv

August 25, 2016
Research and Development, Sales and Marketing Amgen, FDA, par

Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026